Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Enoxacin

Enoxacin: A Comprehensive Overview

Introduction

Enoxacin is a synthetic fluoroquinolone antibiotic that was introduced in the 1980s for the treatment of various bacterial infections. Known for its broad-spectrum activity, enoxacin was primarily used to treat urinary tract infections (UTIs) and gonorrhea. Although its use has declined in many countries due to the development of newer antibiotics and concerns over side effects, enoxacin remains a subject of interest in scientific research, particularly for its potential roles beyond antibacterial therapy.

Chemical Structure and Pharmacokinetics

Enoxacin is a 6-fluoronaphthyridinone derivative, structurally related to other fluoroquinolones. It is administered orally and is rapidly absorbed from the gastrointestinal tract. Peak plasma concentrations are typically achieved within 1 to 2 hours after ingestion. The drug is widely distributed throughout the body, including in tissues and fluids. Enoxacin has a serum elimination half-life of approximately 6 hours in individuals with normal renal function. It is primarily excreted unchanged in the urine, making it particularly effective for treating urinary tract infections.

Mechanism of Action

Enoxacin exerts its antibacterial effects by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. By interfering with these enzymes, enoxacin disrupts bacterial DNA processes, leading to cell death. This mechanism is common among fluoroquinolones and contributes to their broad-spectrum activity against both Gram-negative and Gram-positive bacteria.

Clinical Uses

Enoxacin was approved for the treatment of several bacterial infections, including:

  • Urinary Tract Infections (UTIs): Enoxacin was effective in treating both uncomplicated and complicated UTIs, owing to its high urinary concentrations.

  • Gonorrhea: The drug was used to treat uncomplicated gonorrhea caused by Neisseria gonorrhoeae, including strains resistant to penicillin.

  • Prostatitis: Enoxacin demonstrated efficacy in treating bacterial prostatitis due to its good tissue penetration.

  • Other Infections: It was also used for respiratory tract infections, skin infections, and gastrointestinal infections, although these were not its primary indications.

Dosage and Administration

Enoxacin was typically administered orally in tablet form. The usual adult dosage for UTIs was 200 mg to 400 mg every 12 hours for 7 to 14 days, depending on the severity of the infection. For the treatment of gonorrhea, a single 400 mg dose was often sufficient. The tablets should be taken with a full glass of water, and patients were advised to avoid taking the medication with dairy products or antacids containing magnesium or aluminum, as these could interfere with drug absorption.

Efficacy and Clinical Trials

Clinical studies demonstrated that enoxacin was effective in treating UTIs and gonorrhea. In uncontrolled trials, clinical cure or improvement occurred in 94% to 100% of patients, with bacteriological eradication rates ranging from 82% to 100%. Comparative trials showed satisfactory clinical results in 67% to 96% of patients and bacteriological success in 77% to 98% of cases. These findings underscored enoxacin's efficacy as an antibacterial agent during its period of use.

Adverse Effects

While enoxacin was generally well-tolerated, it was associated with several side effects:

  • Gastrointestinal: Nausea, vomiting, diarrhea, and abdominal discomfort were among the most common adverse effects.

  • Central Nervous System: Headache, dizziness, lightheadedness, and, in rare cases, seizures and psychoses were reported.

  • Dermatologic: Photosensitivity reactions, including increased sensitivity to sunlight, could occur.

  • Musculoskeletal: Enoxacin, like other fluoroquinolones, was associated with tendonitis and tendon rupture, particularly in older adults and those on corticosteroid therapy.

  • Hypersensitivity Reactions: Rash, pruritus, and, rarely, anaphylaxis were observed.

Patients were advised to report any unusual symptoms to their healthcare provider promptly.

Contraindications and Precautions

Enoxacin was contraindicated in individuals with known hypersensitivity to fluoroquinolones. Caution was advised in patients with a history of seizures or other central nervous system disorders, as the drug could lower the seizure threshold. Due to potential effects on cartilage development, enoxacin was generally avoided in children and adolescents, except when no alternative treatments were available. Renal function should be assessed before initiating therapy, and dosage adjustments were necessary for patients with impaired renal function.

Drug Interactions

Enoxacin could interact with several other medications:

  • Theophylline: Enoxacin inhibited the metabolism of theophylline, leading to increased serum concentrations and potential toxicity.

  • Antacids: Concurrent use of antacids containing magnesium or aluminum could reduce enoxacin absorption.

  • Warfarin: Enoxacin could enhance the effects of warfarin, increasing the risk of bleeding.

Patients were advised to inform their healthcare providers of all medications they were taking to avoid potential interactions.

Withdrawal and Current Status

Enoxacin has been withdrawn from the market in several countries, including the United States, due to safety concerns and the availability of newer antibiotics with improved safety profiles. However, generic versions may still be available in some regions. Despite its withdrawal from clinical use, enoxacin continues to be of interest in scientific research.

Emerging Research and Potential New Applications

Recent studies have explored enoxacin's potential beyond its antibacterial properties:

  • Anticancer Activity: Enoxacin has been found to enhance the production of microRNAs by activating the enzyme DICER1, leading to the suppression of tumor growth in certain cancer models. Its ability to interfere with cancer cell proliferation and promote apoptosis is being investigated as a potential therapeutic avenue.

  • Amyotrophic Lateral Sclerosis (ALS): A phase Ib/IIa clinical trial evaluated enoxacin in patients with ALS. The study found that enoxacin was safe and tolerable, with evidence of target engagement, suggesting potential for further research in neurodegenerative diseases.

  • Polycystic Ovary Syndrome (PCOS): In animal models, enoxacin has been shown to ameliorate PCOS symptoms by promoting the browning of white adipose tissue and improving metabolic parameters. These findings indicate a possible role for enoxacin in managing metabolic disorders.

Conclusion

Enoxacin was a valuable antibiotic in the treatment of various bacterial infections, particularly UTIs and gonorrhea. While its clinical use has declined due to safety concerns and the development of newer agents, ongoing research into its effects on microRNA processing and potential applications in cancer and neurodegenerative diseases highlights its continued relevance in biomedical science. As our understanding of enoxacin's mechanisms expands, it may find new roles in therapeutic interventions beyond its original antibacterial indications.